Myovant Sciences Ltd. (MYOV)
Market Cap | 2.61B |
Revenue (ttm) | 379.11M |
Net Income (ttm) | -183.77M |
Shares Out | 97.10M |
EPS (ttm) | -1.91 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 535,588 |
Open | 26.88 |
Previous Close | 26.90 |
Day's Range | 26.87 - 26.90 |
52-Week Range | 7.67 - 27.03 |
Beta | 2.20 |
Analysts | Buy |
Price Target | 27.54 (+2.46%) |
Earnings Date | Jan 26, 2023 |
About MYOV
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduc... [Read more]
Financial Performance
In 2022, MYOV's revenue was $230.97 million, an increase of 289.39% compared to the previous year's $59.32 million. Losses were -$205.98 million, -19.27% less than in 2021.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is $27.54, which is an increase of 2.46% from the latest price.
News

Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
BASEL, Switzerland, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empower...

MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Scienc...

MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
NEW ORLEANS , Jan. 11, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences
NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Myovant Sciences (NYSE: MYOV) by affiliates of its controlling shareh...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, emp...

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms...

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educationa...

SHAREHOLDER ALERT: Weiss Law Reminds MYOV, KNBE, LMST, and PEBO Shareholders About Its Ongoing Investigations
NEW YORK , Nov. 1, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights ...

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet
IRVINE, Calif.

Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
BASEL, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, emp...

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Myovant Sciences Ltd. - MYOV
NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

SHAREHOLDER ALERT: Weiss Law Investigates Myovant Sciences Ltd.
NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Myovant Sciences Ltd. ("Myovant" or the...

Myovant Sciences Cancels Second Quarter Earnings Conference Call
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 202...

MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV) that they don't already own. Furtherm...

Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.

Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.

MYOV STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Myovant Sciences Ltd. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Myovant Sciences Ltd.

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate C...

CORRECTION -- Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today b...

Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for i...

Myovant stock opened 35% up on Monday: here's the catalyst
Myovant Sciences Ltd (NYSE: MYOV) opened nearly 35% up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a b...

Why Is Myovant Sciences (MYOV) Stock Up 30% Today?
Myovant Sciences (NYSE: MYOV) stock is skyrocketing over 30% today on news that the British biopharmaceutical company has received a buyout offer. MYOV stock surged as much as 31% in premarket tradin...

Myovant Stock Soars After Rejecting $2.5 Billion Sumitomo Bid
The offer came at a 27% premium to Myovant's previous market price but was below the company's trading highs last year.